CRX-527 as a candidate adjuvant in a recombinant BCG-based malaria vaccine
- Author:
Nor Munirah Zakaria
1
;
Muhammad Adamu Abbas
2
;
Rapeah Suppian
1
Author Information
- Publication Type:Journal Article
- Keywords: CRX-527; BCG; BCG-MSP-1C; TLR-4 agonists; Cytokine; IgG; Malaria
- From:Asian Pacific Journal of Tropical Biomedicine 2024;14(1):1-7
- CountryChina
- Language:English
- Abstract: Abstract: Objective: To investigate the role of CRX-527, a Toll-like receptor 4 agonist, as the possible adjuvant for recombinant Mycobacterium bovis Bacillus Calmette-Guerin expressing merozoite surface protein 1C (BCG-MSP-1C). Methods: The mice were immunized with BCG and BCG-MSP- 1C in the presence and absence of CRX-527. The untreated mice (injected with PBS-T80 only) were the negative control. The ability of CRX-527 to enhance IgG and its subclasses, as well as IL-4 and IFN-γ production in the serum and spleen supernatant was evaluated using ELISA. Results: Mice immunized with BCG-MSP-1C exhibited the highest production of IgGs, IL-4 and IFN-γ after third immunization. In addition, CRX-527 further promoted the production of total IgG and IgG subclasses as well as IFN-γ and IL-4 in the serum and splenocytes of immunized mice. Conclusions: CRX-527 has the potential as an adjuvant candidate for the candidate vaccines. Further study is needed to verify appropriate dosage for immunization and its efficacy.
- Full text:20240101.pdf
